Vol 3 (October 25, 2025): AME Clinical Trials Review

Immunotherapy in early HR⁺ breast cancer: lessons from KN-756 and CM-7FL

Inferiority of coronary paclitaxel-coated balloon angioplasty to sirolimus-eluting stents for de novo non-complex lesions without a restriction of target vessel diameter: the REC-CAGEFREE I trial

Post-CDK4/6i wars in HR⁺/HER2⁻ breast cancer: is elacestrant a solid contender through the lens of precision oncology

Quality of life during treatment with trastuzumab deruxtecan—is quality of life maintained due to high efficacy?

Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: light and gloom

Cabozantinib: a promising advancement in the treatment of advanced neuroendocrine tumors

Early implementation of exercise after breast cancer surgery: insights and opportunity

Sex-specific approach to only optimize acetylsalicylic acid dosing for secondary prevention in cardiovascular disease is definitely questionable—insights from the ADAPTABLE trial and beyond

The central nervous system protective activity of selpercatinib from LIBRETTO-431

Recent updates in targeted therapy for advanced non-small cell lung cancer with actionable genomic alterations: a narrative review